MARKET

ALKS

ALKS

Alkermes Plc
NASDAQ
29.98
+0.60
+2.04%
Closed 16:20 07/09 EDT
OPEN
29.66
PREV CLOSE
29.38
HIGH
30.03
LOW
29.55
VOLUME
2.04M
TURNOVER
0
52 WEEK HIGH
36.45
52 WEEK LOW
22.90
MARKET CAP
4.94B
P/E (TTM)
14.26
1D
5D
1M
3M
1Y
5Y
1D
Alkermes (NASDAQ:ALKS) shareholders have earned a 9.3% CAGR over the last five years
Simply Wall St · 2d ago
Weekly Report: what happened at ALKS last week (0630-0704)?
Weekly Report · 3d ago
Zacks Industry Outlook Highlights Exelixis, Verona Pharma, Alkermes, Kiniska Pharmaceuticals and Immunocore
NASDAQ · 6d ago
5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment
NASDAQ · 07/02 13:28
FDA flags possible safety signals in new report, says RBC Capital
TipRanks · 06/30 15:50
Weekly Report: what happened at ALKS last week (0623-0627)?
Weekly Report · 06/30 09:06
Weekly Report: what happened at ALKS last week (0616-0620)?
Weekly Report · 06/23 09:06
Stifel Nicolaus Sticks to Their Buy Rating for Alkermes (ALKS)
TipRanks · 06/22 16:55
More
About ALKS
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Webull offers Alkermes Plc stock information, including NASDAQ: ALKS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALKS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALKS stock methods without spending real money on the virtual paper trading platform.